Autologous Transplantation for Newly Diagnosed Multiple Myeloma
This systematic review and meta-analysis reviews phase 3 randomized clinical trials of high-dose therapy followed by autologous stem cell transplant in patients with multiple myeloma.
Related Articles
Clinical Chief – Cellular Therapy (ACT) – Medical Oncology
Title: Clinical Chief – Cellular Therapy (ACT) – Medical Oncology Job Type: Regular Company: Roswell Park Comprehensive Cancer Center Department: Department of Medicine – Lymphoma…
Preprint Servers have Repeatedly Censored our Work on COVID-19 Policy
MedRxiv, SSRN have repeatedly taken down or blocked preprints on articles critical of the CDC, masks, or vaccine mandates
Democrats’ new push to stop RFK Jr.: Highlight Samoa’s measles outbreak
They say the island’s public health crisis, which followed Kennedy’s meeting with local anti-vaccine activists, reveals the consequences of questioning vaccines.
Tarlatamab approved to treat adult patients with small cell lung cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 31 December 2024, approved the medicine tarlatamab (Imdylltra) to treat adult patients with small cell…
Allogeneic Stem Cell Donation
This JAMA Insights discusses allogenic stem cell donation, including the donation process and the effects of stem cell donation on donors.
Preexposure Prophylaxis (PrEP) for HIV
This JAMA Insights discusses the expanding PrEP options for preventing HIV, including the considerations for initiation and follow-up and implementation challenges of these medications.
Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends
This study assesses the association of citywide doxycycline postexposure prophylaxis guideline release with reported chlamydia, gonorrhea, and early syphilis cases in men who have sex…
Tumor-Infiltrating Lymphocytes Therapy Now Available for Treating Unresectable or Metastatic Melanoma
When the FDA granted accelerated approval of tumor-infiltrating lymphocyte (TIL) treatment with lifileucel for patients with metastatic melanoma, Cleveland Clinic Cancer Institute was one of…
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment…
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Key PointsDexamethasone dose reductions <40 to 60 mg weekly are common in multiple myeloma, even for patients enrolled on clinical trials.In our large a
